Patent EP0181150B1 successfully refreshed from Google Patents.
EP0181150B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1985-10-30
•
Granted: 1993-06-09
•
Expires: 2005-10-30
Abstract
Abstract Recombinant hTLR proteins are made using expression vectors containing DNA constructs derived from ARV-2 nucleic acid. These proteins are useful in serological immunoassays to detect antibodies to hTLR.
Inventors
- 👤 Paul A. Luciw
- 👤 Dino Dina
- 👤 Kathelyn Steimer
- 👤 Ray Sanchez Pescador
- 👤 Carlos George-Nascimento
- 👤 Deborah Parkes
- 👤 Rob Hallewell
- 👤 Philip J. Barr
- 👤 Martha Truett
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 04:59
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; A61P37/00; A61P37/02; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/80; C12N15/81; C12N15/85; C12N9/00; C12N9/0004; C12N9/0089; C12Q; C12Q1/00; C12Q1/70; C12Q1/701; C12Q1/702; C12Q1/703; A61K; A61K38/00; C07K2319/00; C07K2319/40; C07K2319/70; C07K2319/735; C07K2319/74; C07K2319/75; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16111; C12N2740/16122; C12N2740/16211; C12N2740/16222; C12N2800/00; C12N2800/10; C12N2800/108; C12N2830/00; C12N2830/001; C12N2830/002; C12N2830/005; C12N2830/15; C12N2830/36; C12N2830/55; C12N2830/70; C12N2830/702; C12N2830/704; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/82; Y10S435/8215; Y10S435/948; Y10S435/974; Y10S435/975; Y10S530/00; Y10S530/82; Y10S530/826
Claims Analysis
Total Claims: 42
Claim 1
Independent Claim
91 words
A recombinant DNA construct useful for the expression of a recombinant polypeptide in a cell containing the construct, the construct comprising control sequences which regulate transcription and translation of the recombinant polypeptide in the cell and a coding sequence regulated by the control sequences, wherein the coding sequence comprises a DNA sequence of at least about 21 bp in reading frame characterised in that the DNA sequence encodes an antigenic HIV-I amino acid sequence of Figure 2 which sequence is immunologically non-cross-reactive with HTLV-I and HTLV-II and is reactive with HIV-I.
Claim 2
Dependent Claim
91 words
A recombinant DNA construct useful for the expression of a recombinant polypeptide in a cell containing the construct, the construct comprising control sequences which regulate transcription and translation of the recombinant polypeptide in the cell and a coding sequence regulated by the control sequences, wherein the coding sequence comprises a DNA sequence of at least about 21 bp in reading frame characterised in that the DNA sequence encodes an antigenic HIV-I amino acid sequence of Figure 2 which sequence is immunologically non-cross-reactive with HTLV-I and HTLV-II and is reactive with HIV-I.
Claim 3
Dependent Claim
17 words
A recombinant DNA construct according to claim 1, which is useful for expression in a eucaryotic cell.
Claim 4
Dependent Claim
17 words
A recombinant DNA construct according to claim 1, which is useful for expression in a yeast cell.
Claim 5
Dependent Claim
17 words
A recombinant DNA construct according to claim 1 which is useful for expression in a bacterial cell.
Claim 6
Dependent Claim
30 words
A recombinant DNA construct according to any one of claims 1 to 4, characterized in that the DNA sequence encodes an amino acid sequence from an env polypeptide of HIV-I.
Claim 7
Dependent Claim
17 words
A recombinant DNA construct according to claim 5, wherein the DNA sequence encodes a complete env polypeptide.
Claim 8
Dependent Claim
30 words
A recombinant DNA construct according to any one of claims 1 to 4, characterised in that the DNA sequence encodes an amino acid sequence from a gag polypeptide of HIV-I.
Claim 9
Dependent Claim
17 words
A recombinant DNA construct according to claim 7, wherein the DNA sequence encodes a complete gag polypeptide.
Claim 10
Dependent Claim
29 words
A recombinant DNA construct according to any one of claims 1 to 4, characterised in that the DNA sequence encodes an amino sequence from a pol polypeptide of HIV-I.
Claim 11
Dependent Claim
17 words
A recombinant DNA construct according to claim 9, wherein the DNA sequence encodes a complete pol polypeptide.
Claim 12
Dependent Claim
42 words
A cell comprising a recombinant DNA construct according to any one of claims 1 to 10, wherein the cell expresses the antigenic HIV-I amino acid sequence and is free from other cells which do not express the antigenic HIV-I amino acid sequence.
Claim 13
Dependent Claim
19 words
A cell according to claim 11, wherein the recombinant DNA construct comprises a replication system recognised by the cell.
Claim 14
Dependent Claim
11 words
A cell according to claim 12 wherein the cell is eukaryotic.
Claim 15
Dependent Claim
15 words
A cell according to any one of claims 11 to 13, which is a yeast.
Claim 16
Dependent Claim
33 words
A method of producing a recombinant polypeptide comprising an antigenic HIV-I amino acid sequence wherein a population of cells according to claim 11 is cultured under conditions whereby the recombinant polypeptide is expressed.
Claim 17
Dependent Claim
11 words
A method according to claim 15, wherein the cells are eukaryotic.
Claim 18
Dependent Claim
13 words
A method according to claim 15, wherein the cells are yeast or bacteria.
Claim 19
Dependent Claim
61 words
An immunoassay for detecting antibodies to HIV-I in a sample suspected of containing the antibodies, characterised in that at least one recombinant polypeptide is used to bind the antibodies and the recombinant polypeptide comprises an antigenic env, gag or pol HIV-I amino acid sequence contained in the sequence shown in Figure 2, which polypeptide is immunologically non-cross-reactive with HTLV-I and HTLV-II.
Claim 20
Dependent Claim
61 words
An immunoassay for detecting antibodies to HIV-I in a sample suspected of containing the antibodies, characterised in that at least one recombinant polypeptide is used to bind the antibodies and the recombinant polypeptide comprises an antigenic env, gag or pol HIV-I amino acid sequence contained in the sequence shown in Figure 2, which polypeptide is immunologically non-cross-reactive with HTLV-I and HTLV-II.
Claim 21
Dependent Claim
26 words
An immunoassay according to claim 18, wherein at least one env amino acid sequence and one gag amino acid sequence are used to bind the antibodies.
Claim 22
Dependent Claim
21 words
An immunoassay according to claim 19, wherein at least one pol amino acid sequence is also used to bind the antibodies.
Claim 23
Dependent Claim
67 words
A diagnostic reagent, immunogen or vaccine capable of binding an anti-HIV-I antibody in human serum characterised in that said reagent, immunogen or vaccine consists of an antigen comprising an immunogenic fragment of at least seven amino acids of an HIV-I env, gag or pol polypeptide, which fragment is immunologically non-cross-reactive with HTLV-I and HTLV-II and which has a sequence contained in the sequence shown in Figure 2.
Claim 24
Dependent Claim
67 words
A diagnostic reagent, immunogen or vaccine capable of binding an anti-HIV-I antibody in human serum characterised in that said reagent, immunogen or vaccine consists of an antigen comprising an immunogenic fragment of at least seven amino acids of an HIV-I env, gag or pol polypeptide, which fragment is immunologically non-cross-reactive with HTLV-I and HTLV-II and which has a sequence contained in the sequence shown in Figure 2.
Claim 25
Dependent Claim
22 words
A recombinant polypeptide characterised in that it is produced by a cell transformed by a recombinant DNA construct according to claim 5.
Claim 26
Dependent Claim
22 words
A recombinant polypeptide characterised in that it is produced by a cell transformed by a recombinant DNA construct according to claim 6.
Claim 27
Dependent Claim
22 words
A recombinant polypeptide characterised in that it is produced by a cell transformed by a recombinant DNA construct according to claim 7.
Claim 28
Dependent Claim
16 words
A recombinant polypeptide according to claim 24, wherein the gag amino acid sequence comprises p16 gag.
Claim 29
Dependent Claim
16 words
A recombinant polypeptide according to claim 24, wherein the gag amino acid sequence comprises p25 gag.
Claim 30
Dependent Claim
26 words
A recombinant polypeptide according to claim 24, wherein the gag amino acid sequence comprises a fusion protein of p16 gag and p25 gag amino acid sequences.
Claim 31
Dependent Claim
22 words
A recombinant polypeptide characterised in that it is produced by a cell transformed by a recombinant DNA construct according to claim 10.
Claim 32
Dependent Claim
16 words
A recombinant polypeptide according to claim 28, wherein the pol amino acid sequence comprises p31 pol.
Claim 33
Dependent Claim
26 words
A recombinant polypeptide according to claim 28, wherein the pol amino acid sequence comprises a fusion protein of superoxide dismutase and p31 pol amino acid sequences.
Claim 34
Dependent Claim
30 words
An article of manufacture for use in an immunoassay for HIV-I antibodies characterised in that it comprises a solid support having bound thereto a recombinant polypeptide according to claim 22.
Claim 35
Dependent Claim
29 words
An article of manufacture for use in an immunoassay for HIV-I antibodies characterised in that it comprises a solid support having bound thereto recombinant polypeptide according to claim 24.
Claim 36
Dependent Claim
30 words
An article of manufacture for use in an immunoassay for HIV-I antibodies characterised in that it comprises a solid support having bound thereto a recombinant polypeptide according to claim 28.
Claim 37
Dependent Claim
29 words
A DNA sequence encoding a HIV-I polypeptide derived from a phage selected from ARV-2 (7D) (ATCC No. 40143), ARV-2 (8A) (ATCC No. 40144), and ARV-2 (9B) (ATCC No. 40158).
Claim 38
Dependent Claim
29 words
A DNA sequence encoding a HIV-I polypeptide derived from a phage selected from ARV-2 (7D) (ATCC No. 40143), ARV-2 (8A) (ATCC No. 40144), and ARV-2 (9B) (ATCC No. 40158).
Claim 39
Dependent Claim
28 words
A recombinant DNA construct capable of expressing an antigenic recombinant HIV-I polypeptide derived from an organism selected from ATCC No. 53246, ATCC No. 20769 and ATCC No. 20768.
Claim 40
Dependent Claim
28 words
A recombinant DNA construct capable of expressing an antigenic recombinant HIV-I polypeptide derived from an organism selected from ATCC No. 53246, ATCC No. 20769 and ATCC No. 20768.
Claim 41
Dependent Claim
212 words
An isolated polynucleotide comprising the ARV-2 sequence of Figure 2 or a fragment of at least 21 bp thereof, provided that said fragment of at least 21 bp is not i) a 3.5 kb viral insert from HTLV-III recombinant clone BH5, ii) a 5.5 kb viral insert from HTLV-III recombinant clone BH8, or iii) a 9.0 kb viral insert from HTLV-!!! recombinant clone BH10 disclosed in published European patent application EP-A1-0173529 further provided that said fragment of at least 21 bp is not a) a 0.6 kbp viral insert from LAV designated LAV75, b) a 0.8 kbp viral insert from LAV designated LAV82, c) a 2.5 kbp viral insert from LAV designated LAV13, d) a 9.1 to 9.2 kbp viral insert from phage XJ19, e) a DNA fragment extending from Kpnl (6100) to approximately BamHl (8150) of λJ19, f) a DNA fragment extending from approximately Kpnl (3500) to approximately Bgllll (6500) of λJ19, or g) a DNA fragment extending from approximately Pst(800) to approximately Kpnl(3500) of λJ19 disclosed in published European patent application EP-A1-0178978 further provided that said fragment of at least 21 bp is not I a 2.3 kbp Kpnl-Kpnl fragment, II a 1.0 kbp EcoRl-EcoRl fragment, or III a 2.4 kbp EcoRl-Hindlll fragment disclosed in published European patent application EP-A2-0185444.
Claim 42
Dependent Claim
212 words
An isolated polynucleotide comprising the ARV-2 sequence of Figure 2 or a fragment of at least 21 bp thereof, provided that said fragment of at least 21 bp is not i) a 3.5 kb viral insert from HTLV-III recombinant clone BH5, ii) a 5.5 kb viral insert from HTLV-III recombinant clone BH8, or iii) a 9.0 kb viral insert from HTLV-!!! recombinant clone BH10 disclosed in published European patent application EP-A1-0173529 further provided that said fragment of at least 21 bp is not a) a 0.6 kbp viral insert from LAV designated LAV75, b) a 0.8 kbp viral insert from LAV designated LAV82, c) a 2.5 kbp viral insert from LAV designated LAV13, d) a 9.1 to 9.2 kbp viral insert from phage XJ19, e) a DNA fragment extending from Kpnl (6100) to approximately BamHl (8150) of λJ19, f) a DNA fragment extending from approximately Kpnl (3500) to approximately Bgllll (6500) of λJ19, or g) a DNA fragment extending from approximately Pst(800) to approximately Kpnl(3500) of λJ19 disclosed in published European patent application EP-A1-0178978 further provided that said fragment of at least 21 bp is not I a 2.3 kbp Kpnl-Kpnl fragment, II a 1.0 kbp EcoRl-EcoRl fragment, or III a 2.4 kbp EcoRl-Hindlll fragment disclosed in published European patent application EP-A2-0185444.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.